Why the study?
Does routine cardiac monitoring provide clinical utility in breast cancer patients receiving trastuzumab?
Does routine cardiac monitoring provide clinical utility in breast cancer patients receiving trastuzumab?
Less frequent cardiac monitoring may be justified in breast cancer patients on trastuzumab due to the low incidence of clinically significant heart failure.
Answers are grounded in this paper and cite their sources.
Supports exploring reduced monitoring in trastuzumab recipients; leaves open prospective validation before practice change.
Given the low incidence of clinically significant HF and cost of monitoring, less frequent monitoring may be justified.
No takes yet. Share an insight, caveat, or question.
Davis et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: